COVID-19 in persons with haematological cancers
Infection with SARS-CoV-2, the cause of coronavirus infectious disease–19 (COVID-19), has caused a pandemic with >850,000 cases worldwide and increasing. Several studies report outcomes of COVID-19 in predominately well persons. There are also some data on COVID-19 in persons with predominately s...
Saved in:
| Published in | Leukemia Vol. 34; no. 6; pp. 1637 - 1645 |
|---|---|
| Main Authors | , , , , , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
London
Nature Publishing Group UK
01.06.2020
Nature Publishing Group |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0887-6924 1476-5551 1476-5551 |
| DOI | 10.1038/s41375-020-0836-7 |
Cover
| Abstract | Infection with SARS-CoV-2, the cause of coronavirus infectious disease–19 (COVID-19), has caused a pandemic with >850,000 cases worldwide and increasing. Several studies report outcomes of COVID-19 in predominately well persons. There are also some data on COVID-19 in persons with predominately solid cancer but controversy whether these persons have the same outcomes. We conducted a cohort study at two centres in Wuhan, China, of 128 hospitalised subjects with haematological cancers, 13 (10%) of whom developed COVID-19. We also studied 226 health care providers, 16 of whom developed COVID-19 and 11 of whom were hospitalised. Co-variates were compared with the 115 subjects with haematological cancers without COVID-19 and with 11 hospitalised health care providers with COVID-19. There were no significant differences in baseline co-variates between subjects with haematological cancers developing or not developing COVID-19. Case rates for COVID-19 in hospitalised subjects with haematological cancers was 10% (95% Confidence Interval [CI], 6, 17%) compared with 7% (4, 12%;
P
= 0.322) in health care providers. However, the 13 subjects with haematological cancers had more severe COVID-19 and more deaths compared with hospitalised health care providers with COVID-19. Case fatality rates were 62% (32, 85%) and 0 (0, 32%;
P
= 0.002). Hospitalised persons with haematological cancers have a similar case rate of COVID-19 compared with normal health care providers but have more severe disease and a higher case fatality rate. Because we were unable to identify specific risk factors for COVID-19 in hospitalised persons with haematological cancers, we suggest increased surveillance and possible protective isolation. |
|---|---|
| AbstractList | Infection with SARS-CoV-2, the cause of coronavirus infectious disease-19 (COVID-19), has caused a pandemic with >850,000 cases worldwide and increasing. Several studies report outcomes of COVID-19 in predominately well persons. There are also some data on COVID-19 in persons with predominately solid cancer but controversy whether these persons have the same outcomes. We conducted a cohort study at two centres in Wuhan, China, of 128 hospitalised subjects with haematological cancers, 13 (10%) of whom developed COVID-19. We also studied 226 health care providers, 16 of whom developed COVID-19 and 11 of whom were hospitalised. Co-variates were compared with the 115 subjects with haematological cancers without COVID-19 and with 11 hospitalised health care providers with COVID-19. There were no significant differences in baseline co-variates between subjects with haematological cancers developing or not developing COVID-19. Case rates for COVID-19 in hospitalised subjects with haematological cancers was 10% (95% Confidence Interval [CI], 6, 17%) compared with 7% (4, 12%; P = 0.322) in health care providers. However, the 13 subjects with haematological cancers had more severe COVID-19 and more deaths compared with hospitalised health care providers with COVID-19. Case fatality rates were 62% (32, 85%) and 0 (0, 32%; P = 0.002). Hospitalised persons with haematological cancers have a similar case rate of COVID-19 compared with normal health care providers but have more severe disease and a higher case fatality rate. Because we were unable to identify specific risk factors for COVID-19 in hospitalised persons with haematological cancers, we suggest increased surveillance and possible protective isolation. Infection with SARS-CoV-2, the cause of coronavirus infectious disease-19 (COVID-19), has caused a pandemic with >850,000 cases worldwide and increasing. Several studies report outcomes of COVID-19 in predominately well persons. There are also some data on COVID-19 in persons with predominately solid cancer but controversy whether these persons have the same outcomes. We conducted a cohort study at two centres in Wuhan, China, of 128 hospitalised subjects with haematological cancers, 13 (10%) of whom developed COVID-19. We also studied 226 health care providers, 16 of whom developed COVID-19 and 11 of whom were hospitalised. Co-variates were compared with the 115 subjects with haematological cancers without COVID-19 and with 11 hospitalised health care providers with COVID-19. There were no significant differences in baseline co-variates between subjects with haematological cancers developing or not developing COVID-19. Case rates for COVID-19 in hospitalised subjects with haematological cancers was 10% (95% Confidence Interval [CI], 6, 17%) compared with 7% (4, 12%; P = 0.322) in health care providers. However, the 13 subjects with haematological cancers had more severe COVID-19 and more deaths compared with hospitalised health care providers with COVID-19. Case fatality rates were 62% (32, 85%) and 0 (0, 32%; P = 0.002). Hospitalised persons with haematological cancers have a similar case rate of COVID-19 compared with normal health care providers but have more severe disease and a higher case fatality rate. Because we were unable to identify specific risk factors for COVID-19 in hospitalised persons with haematological cancers, we suggest increased surveillance and possible protective isolation.Infection with SARS-CoV-2, the cause of coronavirus infectious disease-19 (COVID-19), has caused a pandemic with >850,000 cases worldwide and increasing. Several studies report outcomes of COVID-19 in predominately well persons. There are also some data on COVID-19 in persons with predominately solid cancer but controversy whether these persons have the same outcomes. We conducted a cohort study at two centres in Wuhan, China, of 128 hospitalised subjects with haematological cancers, 13 (10%) of whom developed COVID-19. We also studied 226 health care providers, 16 of whom developed COVID-19 and 11 of whom were hospitalised. Co-variates were compared with the 115 subjects with haematological cancers without COVID-19 and with 11 hospitalised health care providers with COVID-19. There were no significant differences in baseline co-variates between subjects with haematological cancers developing or not developing COVID-19. Case rates for COVID-19 in hospitalised subjects with haematological cancers was 10% (95% Confidence Interval [CI], 6, 17%) compared with 7% (4, 12%; P = 0.322) in health care providers. However, the 13 subjects with haematological cancers had more severe COVID-19 and more deaths compared with hospitalised health care providers with COVID-19. Case fatality rates were 62% (32, 85%) and 0 (0, 32%; P = 0.002). Hospitalised persons with haematological cancers have a similar case rate of COVID-19 compared with normal health care providers but have more severe disease and a higher case fatality rate. Because we were unable to identify specific risk factors for COVID-19 in hospitalised persons with haematological cancers, we suggest increased surveillance and possible protective isolation. Infection with SARS-CoV-2, the cause of coronavirus infectious disease–19 (COVID-19), has caused a pandemic with >850,000 cases worldwide and increasing. Several studies report outcomes of COVID-19 in predominately well persons. There are also some data on COVID-19 in persons with predominately solid cancer but controversy whether these persons have the same outcomes. We conducted a cohort study at two centres in Wuhan, China, of 128 hospitalised subjects with haematological cancers, 13 (10%) of whom developed COVID-19. We also studied 226 health care providers, 16 of whom developed COVID-19 and 11 of whom were hospitalised. Co-variates were compared with the 115 subjects with haematological cancers without COVID-19 and with 11 hospitalised health care providers with COVID-19. There were no significant differences in baseline co-variates between subjects with haematological cancers developing or not developing COVID-19. Case rates for COVID-19 in hospitalised subjects with haematological cancers was 10% (95% Confidence Interval [CI], 6, 17%) compared with 7% (4, 12%; P = 0.322) in health care providers. However, the 13 subjects with haematological cancers had more severe COVID-19 and more deaths compared with hospitalised health care providers with COVID-19. Case fatality rates were 62% (32, 85%) and 0 (0, 32%; P = 0.002). Hospitalised persons with haematological cancers have a similar case rate of COVID-19 compared with normal health care providers but have more severe disease and a higher case fatality rate. Because we were unable to identify specific risk factors for COVID-19 in hospitalised persons with haematological cancers, we suggest increased surveillance and possible protective isolation. |
| Audience | Academic |
| Author | Chen, Wenlan Liang, Bo Ma, Yanling Yuan, Guolin Chen, Lei Chen, Zhichao He, Wenjuan Chen, Li Wu, Di Wang, Hongxiang Li, Qiubai Gale, Robert Peter Lu, Xiaoting Li, Lei Fang, Yun |
| Author_xml | – sequence: 1 givenname: Wenjuan surname: He fullname: He, Wenjuan organization: Institute of Haematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology – sequence: 2 givenname: Lei surname: Chen fullname: Chen, Lei organization: Institute of Haematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology – sequence: 3 givenname: Li surname: Chen fullname: Chen, Li organization: Department of Haematology, Wuhan Central Hospital, Tongji Medical College, Huazhong University of Science and Technology – sequence: 4 givenname: Guolin surname: Yuan fullname: Yuan, Guolin organization: Department of Haematology, Xiangyang Central Hospital, The Affiliated Hospital of Hubei University of Arts and Science – sequence: 5 givenname: Yun surname: Fang fullname: Fang, Yun organization: Institute of Haematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology – sequence: 6 givenname: Wenlan surname: Chen fullname: Chen, Wenlan organization: Institute of Haematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology – sequence: 7 givenname: Di surname: Wu fullname: Wu, Di organization: Institute of Haematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology – sequence: 8 givenname: Bo surname: Liang fullname: Liang, Bo organization: Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology – sequence: 9 givenname: Xiaoting surname: Lu fullname: Lu, Xiaoting organization: Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology – sequence: 10 givenname: Yanling surname: Ma fullname: Ma, Yanling organization: Department of Respiratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology – sequence: 11 givenname: Lei surname: Li fullname: Li, Lei organization: Wuhan Jin-Yin-Tan Hospital – sequence: 12 givenname: Hongxiang surname: Wang fullname: Wang, Hongxiang email: whitely1972@sina.com organization: Department of Haematology, Wuhan Central Hospital, Tongji Medical College, Huazhong University of Science and Technology – sequence: 13 givenname: Zhichao surname: Chen fullname: Chen, Zhichao email: chenzhichao@hust.edu.cn organization: Institute of Haematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology – sequence: 14 givenname: Qiubai orcidid: 0000-0001-7884-0745 surname: Li fullname: Li, Qiubai email: qiubaili@hust.edu.cn organization: Institute of Haematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology – sequence: 15 givenname: Robert Peter surname: Gale fullname: Gale, Robert Peter organization: Centre for Haematology Research, Department of Immunology and Inflammation, Imperial College London |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/32332856$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kl1LHDEUhkNR6qr9Ab0pA4XSm9F8f9wUZPuhIHjTehtiNrMTySTbZMbSf98Mq9WVVnIxkPO8b8685xyCvZiiA-AtgicIEnlaKCKCtRDDFkrCW_EKLBAVvGWMoT2wgFKKlitMD8BhKbcQzkX-GhwQTAiWjC_A6fLq-uJzi1TjY7NxuaRYml9-7JveuMGMKaS1tyY01kRby8dgvzOhuDf33yPw4-uX78vz9vLq28Xy7LK1TPGx5Yw5qYyjDBLElRVUMrbivBM3WHKiOoIMtZasOBSo9k8gJdYKhXDHiBGOHIFPW9_NdDO4lXVxzCboTfaDyb91Ml7vVqLv9TrdaYEk5AJXg4_3Bjn9nFwZ9eCLdSGY6NJUNCaKSqEEFxV9_wy9TVOO9fc0poIqiRFHL1M1aYSFxI_U2gSnfexS7c7OT-szjhmHSrGZOvkHVc_KDd7WIXe-3u8IPjwR9M6EsS8pTKOv89oF3z3N7W9gDxOvgNgCNqdSsuu09aOZfWoLPmgE9bxbertbus5Gz7ul55jQM-WD-UsavNWUysa1y4-h_V_0BwVi2es |
| CitedBy_id | crossref_primary_10_1007_s10096_020_04078_1 crossref_primary_10_3390_vaccines11071139 crossref_primary_10_1016_j_coco_2020_100487 crossref_primary_10_1038_s41375_020_0897_7 crossref_primary_10_1111_bjh_16996 crossref_primary_10_1111_ejh_13469 crossref_primary_10_1080_16078454_2022_2089830 crossref_primary_10_1007_s12185_021_03172_0 crossref_primary_10_5812_ijcm_113003 crossref_primary_10_1016_j_blre_2020_100775 crossref_primary_10_58931_cht_2023_2231 crossref_primary_10_1016_j_hemonc_2020_07_005 crossref_primary_10_4103_CRST_CRST_182_20 crossref_primary_10_1002_mog2_58 crossref_primary_10_1182_blood_2020008824 crossref_primary_10_7759_cureus_9629 crossref_primary_10_1080_14737140_2021_1837628 crossref_primary_10_2174_1573406417666210712211557 crossref_primary_10_5501_wjv_v10_i6_312 crossref_primary_10_1002_jmv_26680 crossref_primary_10_1038_s41375_021_01257_7 crossref_primary_10_1001_jamanetworkopen_2022_10880 crossref_primary_10_1186_s13045_020_00970_7 crossref_primary_10_3390_cancers12061581 crossref_primary_10_1007_s11845_020_02303_6 crossref_primary_10_1016_j_beha_2024_101536 crossref_primary_10_1080_07357907_2022_2121966 crossref_primary_10_1002_adfm_202107223 crossref_primary_10_1158_2643_3230_BCD_20_0102 crossref_primary_10_3390_ijerph19084738 crossref_primary_10_4103_joah_joah_71_20 crossref_primary_10_1007_s10495_024_01959_0 crossref_primary_10_1016_j_esmoop_2023_101559 crossref_primary_10_1111_ijlh_13301 crossref_primary_10_7759_cureus_25738 crossref_primary_10_1007_s11042_021_11153_y crossref_primary_10_3390_cancers14102494 crossref_primary_10_1016_j_htct_2021_09_020 crossref_primary_10_1016_j_blre_2021_100914 crossref_primary_10_1002_jcla_24387 crossref_primary_10_1002_jmv_27665 crossref_primary_10_1097_CCE_0000000000000535 crossref_primary_10_3389_fimmu_2020_01294 crossref_primary_10_3389_fimmu_2022_911339 crossref_primary_10_51847_b3k4cePnIA crossref_primary_10_1080_10428194_2020_1834098 crossref_primary_10_3389_fonc_2023_1157610 crossref_primary_10_1111_bjh_16856 crossref_primary_10_1016_j_metop_2021_100116 crossref_primary_10_1080_16078454_2023_2288477 crossref_primary_10_1111_bjh_17027 crossref_primary_10_1055_a_1382_6060 crossref_primary_10_1016_j_critrevonc_2021_103365 crossref_primary_10_1111_ejh_13926 crossref_primary_10_1016_j_ijrobp_2020_06_065 crossref_primary_10_3389_fonc_2020_01270 crossref_primary_10_1038_s41375_020_0910_1 crossref_primary_10_1172_JCI146031 crossref_primary_10_3390_medicina58091215 crossref_primary_10_1002_jmv_26586 crossref_primary_10_2174_1871526523666230502142256 crossref_primary_10_1016_j_bcmd_2020_102525 crossref_primary_10_1080_10428194_2021_1948031 crossref_primary_10_1093_cid_ciaa1339 crossref_primary_10_1038_s41416_021_01500_z crossref_primary_10_1111_bjh_16962 crossref_primary_10_1136_bmjhci_2021_100341 crossref_primary_10_1097_MPH_0000000000002407 crossref_primary_10_1136_jitc_2020_001020 crossref_primary_10_1007_s10495_024_01996_9 crossref_primary_10_1007_s12288_021_01498_7 crossref_primary_10_1007_s10238_023_01027_y crossref_primary_10_1016_j_ijid_2021_04_068 crossref_primary_10_18621_eurj_1251443 crossref_primary_10_1007_s15004_021_8814_4 crossref_primary_10_1111_bjh_17260 crossref_primary_10_2147_IDR_S435160 crossref_primary_10_1200_JCO_20_01580 crossref_primary_10_1093_ofid_ofaa372 crossref_primary_10_3390_v17030404 crossref_primary_10_4103_ijmr_ijmr_1180_21 crossref_primary_10_1038_s41375_020_0960_4 crossref_primary_10_1016_j_mehy_2022_110876 crossref_primary_10_1515_jbcpp_2021_0057 crossref_primary_10_1002_onco_13807 crossref_primary_10_1007_s15010_020_01521_5 crossref_primary_10_1038_s41375_020_0877_y crossref_primary_10_1038_s41375_020_0853_6 crossref_primary_10_1111_bjh_16956 crossref_primary_10_3390_medicina59091564 crossref_primary_10_1111_ijlh_13298 crossref_primary_10_1159_000510178 crossref_primary_10_1002_iub_2536 crossref_primary_10_1038_s41375_020_0914_x crossref_primary_10_3390_pathogens11050567 crossref_primary_10_3390_jcm10071503 crossref_primary_10_1007_s00520_021_06101_3 crossref_primary_10_1186_s12890_025_03524_0 crossref_primary_10_1182_blood_2021012251 crossref_primary_10_1007_s40615_022_01415_2 crossref_primary_10_1080_16078454_2021_1992117 crossref_primary_10_17650_1818_8346_2023_18_4_Suppl__53_63 crossref_primary_10_21802_e_GMJ2024_A01 crossref_primary_10_1007_s00520_020_05744_y crossref_primary_10_1016_j_transci_2021_103104 crossref_primary_10_5501_wjv_v11_i5_321 crossref_primary_10_5812_archcid_107788 crossref_primary_10_1007_s12254_021_00775_5 crossref_primary_10_1371_journal_pone_0267139 crossref_primary_10_1080_0284186X_2020_1863464 crossref_primary_10_3389_fonc_2024_1380492 crossref_primary_10_5500_wjt_v11_i11_480 crossref_primary_10_17116_dokgastro20241303160 crossref_primary_10_1007_s12185_023_03685_w crossref_primary_10_1186_s12879_024_10063_2 crossref_primary_10_1038_s41375_020_0986_7 crossref_primary_10_1097_HS9_0000000000000538 crossref_primary_10_2169_naika_109_2046 crossref_primary_10_4103_mamcjms_mamcjms_83_21 crossref_primary_10_1038_s41375_020_0925_7 crossref_primary_10_3390_jcm13185400 crossref_primary_10_1016_j_eclinm_2020_100549 crossref_primary_10_1111_tid_13477 crossref_primary_10_1002_ccr3_4013 crossref_primary_10_21320_2500_2139_2021_14_2_220_224 crossref_primary_10_1016_j_ctrv_2020_102068 crossref_primary_10_1016_j_ejca_2020_09_009 crossref_primary_10_3389_fonc_2021_740320 crossref_primary_10_1152_physrev_00018_2020 crossref_primary_10_1111_bjh_16935 crossref_primary_10_3390_cancers14051173 crossref_primary_10_1111_nep_13847 crossref_primary_10_1200_OA_24_00034 crossref_primary_10_1038_s41375_020_0959_x crossref_primary_10_1097_HS9_0000000000000432 crossref_primary_10_1016_j_cell_2020_10_049 crossref_primary_10_2196_34128 crossref_primary_10_1136_jitc_2021_002838 crossref_primary_10_3390_diagnostics10120992 crossref_primary_10_7759_cureus_26865 crossref_primary_10_1007_s10875_020_00927_y crossref_primary_10_1111_1759_7714_13710 crossref_primary_10_1007_s00277_020_04184_2 crossref_primary_10_1016_j_jtct_2023_09_027 crossref_primary_10_1038_s41375_020_0887_9 crossref_primary_10_1111_bjh_16801 crossref_primary_10_1371_journal_pone_0271756 crossref_primary_10_1093_jpids_piaa175 crossref_primary_10_1002_ajh_26251 crossref_primary_10_1016_j_clml_2022_07_017 crossref_primary_10_7717_peerj_10599 crossref_primary_10_1111_bjh_17212 crossref_primary_10_1038_s41409_021_01312_y crossref_primary_10_1159_000514071 crossref_primary_10_1007_s00277_020_04328_4 crossref_primary_10_1016_S1470_2045_20_30619_7 crossref_primary_10_1016_j_cmi_2020_12_018 crossref_primary_10_1016_S2352_3026_20_30205_2 crossref_primary_10_3390_healthcare13020157 crossref_primary_10_3389_fmolb_2021_643004 crossref_primary_10_1111_ejh_13552 crossref_primary_10_1200_EDBK_359656 crossref_primary_10_1016_j_leukres_2020_106473 crossref_primary_10_1016_j_jcpo_2022_100340 crossref_primary_10_18787_jr_2023_00015 crossref_primary_10_1200_GO_20_00620 crossref_primary_10_7554_eLife_81127 crossref_primary_10_1007_s12288_020_01318_4 crossref_primary_10_3390_cancers16051055 crossref_primary_10_36401_JIPO_20_34 crossref_primary_10_1007_s15015_020_2437_8 crossref_primary_10_3390_biology12040545 crossref_primary_10_1002_ijc_33601 crossref_primary_10_1080_17474086_2020_1787147 crossref_primary_10_3390_curroncol28020118 crossref_primary_10_3892_ol_2021_13117 crossref_primary_10_1186_s40164_023_00426_x crossref_primary_10_1055_a_1361_7423 crossref_primary_10_1093_jnci_djaa168 crossref_primary_10_1093_trstmh_trac015 crossref_primary_10_1371_journal_pone_0273691 crossref_primary_10_3324_haematol_2020_269878 crossref_primary_10_1016_j_lanepe_2024_101062 crossref_primary_10_1080_10428194_2021_1876865 crossref_primary_10_4103_ejh_ejh_31_22 crossref_primary_10_1016_j_clinthera_2021_03_016 crossref_primary_10_1182_bloodadvances_2020002595 crossref_primary_10_3389_fonc_2020_01578 crossref_primary_10_1016_j_jtct_2020_11_019 crossref_primary_10_17826_cumj_1036774 crossref_primary_10_17116_pain20242203155 crossref_primary_10_1055_a_1192_8742 crossref_primary_10_1016_S2352_3026_20_30186_1 crossref_primary_10_1007_s11912_022_01198_z crossref_primary_10_1080_21642850_2023_2249534 crossref_primary_10_1080_14760584_2021_1932475 crossref_primary_10_1080_14656566_2020_1849143 crossref_primary_10_1007_s00415_020_10311_w crossref_primary_10_1002_bies_202000198 crossref_primary_10_1159_000510769 crossref_primary_10_3389_fonc_2020_01439 crossref_primary_10_1002_cncr_33160 crossref_primary_10_3748_wjg_v28_i39_5666 crossref_primary_10_1007_s00277_021_04644_3 crossref_primary_10_1097_MPH_0000000000002236 crossref_primary_10_3390_cancers12092377 crossref_primary_10_3390_cancers16081606 crossref_primary_10_1007_s10147_020_01837_0 crossref_primary_10_1177_11795549211043427 crossref_primary_10_1038_s41375_020_01070_8 crossref_primary_10_1093_jnci_djab030 crossref_primary_10_1038_s41375_021_01302_5 crossref_primary_10_1007_s40264_021_01131_6 crossref_primary_10_1136_jitc_2020_001314 crossref_primary_10_1016_S1470_2045_20_30442_3 crossref_primary_10_1002_jmv_28487 crossref_primary_10_37989_gumussagbil_961384 crossref_primary_10_1016_j_ccell_2020_09_018 crossref_primary_10_1016_j_lrr_2020_100232 crossref_primary_10_1182_bloodadvances_2021006101 crossref_primary_10_3390_cancers15205066 crossref_primary_10_1007_s11912_021_01111_0 crossref_primary_10_1515_biol_2022_0641 crossref_primary_10_1093_ofid_ofab193 crossref_primary_10_1097_QCO_0000000000000841 crossref_primary_10_3390_antiox9090888 crossref_primary_10_3390_cancers15123115 crossref_primary_10_56083_RCV3N10_002 crossref_primary_10_1038_s41598_021_94630_6 crossref_primary_10_1186_s13027_021_00376_1 crossref_primary_10_12998_wjcc_v9_i28_8441 crossref_primary_10_3390_biomedicines11030926 crossref_primary_10_4274_tjh_galenos_2021_2021_0287 crossref_primary_10_3390_vaccines10020326 crossref_primary_10_1016_j_heliyon_2024_e39044 crossref_primary_10_1016_j_htct_2021_11_015 crossref_primary_10_1186_s12943_024_02153_1 crossref_primary_10_3904_kjim_2021_186 crossref_primary_10_1016_j_ejca_2020_08_011 crossref_primary_10_1016_j_patter_2023_100889 crossref_primary_10_1055_s_0041_1729732 crossref_primary_10_1111_ejh_13519 crossref_primary_10_1590_1980_265x_tce_2020_0415 crossref_primary_10_1111_bjh_17890 crossref_primary_10_3390_metabo14040195 crossref_primary_10_1007_s00520_021_06175_z crossref_primary_10_1002_jmv_26197 crossref_primary_10_1038_s41375_020_0941_7 crossref_primary_10_4103_aam_aam_238_21 crossref_primary_10_3389_fmed_2020_00462 crossref_primary_10_1093_jncics_pkaa102 crossref_primary_10_1002_acg2_88 crossref_primary_10_1038_s41375_020_01019_x crossref_primary_10_1038_s41375_021_01288_0 crossref_primary_10_1038_s41598_021_89182_8 crossref_primary_10_1136_bcr_2021_243469 crossref_primary_10_1007_s00277_024_05869_8 crossref_primary_10_1007_s15010_022_01869_w crossref_primary_10_1093_cid_ciab048 crossref_primary_10_1182_bloodadvances_2020002543 crossref_primary_10_1016_S2352_3026_20_30252_0 crossref_primary_10_1007_s11764_022_01236_6 crossref_primary_10_1038_s41375_021_01450_8 crossref_primary_10_1002_osi2_1188 crossref_primary_10_1080_10428194_2022_2131420 crossref_primary_10_48057_hematologa_v28i1_557 crossref_primary_10_1002_cam4_4888 crossref_primary_10_1371_journal_pone_0291756 crossref_primary_10_1038_s41409_021_01326_6 crossref_primary_10_1001_jamanetworkopen_2022_51165 crossref_primary_10_1177_03000605221082875 crossref_primary_10_12998_wjcc_v9_i18_4859 crossref_primary_10_1016_j_medcle_2023_12_023 crossref_primary_10_1182_blood_2020006965 crossref_primary_10_17650_1818_8346_2022_17_2_95_106 crossref_primary_10_1038_s41375_021_01270_w crossref_primary_10_1007_s00520_022_07199_9 crossref_primary_10_1155_2022_7017317 crossref_primary_10_1631_jzus_B2000423 crossref_primary_10_1182_bloodadvances_2020003883 crossref_primary_10_1007_s00277_023_05204_7 crossref_primary_10_1136_bmjopen_2020_044661 crossref_primary_10_1186_s13027_024_00587_2 crossref_primary_10_1093_cid_ciaa863 crossref_primary_10_1159_000513036 crossref_primary_10_1158_2643_3230_BCD_22_0013 crossref_primary_10_1002_jmv_26404 crossref_primary_10_1016_j_medcli_2023_12_030 crossref_primary_10_5812_ijcm_115735 crossref_primary_10_5306_wjco_v14_i9_343 crossref_primary_10_7717_peerj_12394 crossref_primary_10_3389_fimmu_2023_1125824 crossref_primary_10_1111_ejh_13493 crossref_primary_10_1200_GO_21_00072 crossref_primary_10_1016_j_annonc_2021_07_002 crossref_primary_10_1016_j_jtct_2021_07_008 crossref_primary_10_1016_j_fct_2020_111769 crossref_primary_10_14475_jhpc_2021_24_1_66 crossref_primary_10_3389_fpubh_2023_1245464 crossref_primary_10_3238_PersOnko_2020_08_17_07 crossref_primary_10_1007_s00277_022_05026_z crossref_primary_10_1038_s41375_020_0879_9 crossref_primary_10_1038_s41375_020_01015_1 crossref_primary_10_1186_s12943_021_01363_1 crossref_primary_10_3324_haematol_2021_279216 crossref_primary_10_3390_ijerph18168552 crossref_primary_10_1016_j_jhin_2022_04_011 crossref_primary_10_3390_foods11131925 crossref_primary_10_1002_jmv_26656 crossref_primary_10_1093_cid_ciab1059 crossref_primary_10_1002_jha2_764 crossref_primary_10_1007_s00066_021_01797_y crossref_primary_10_1111_ejh_13967 crossref_primary_10_7759_cureus_14480 crossref_primary_10_7759_cureus_46950 crossref_primary_10_1200_OP_21_00394 crossref_primary_10_1007_s00277_023_05593_9 crossref_primary_10_18621_eurj_1000067 crossref_primary_10_7759_cureus_15452 crossref_primary_10_1080_10428194_2020_1838506 crossref_primary_10_1038_s41409_021_01278_x crossref_primary_10_1016_S2352_3026_20_30251_9 crossref_primary_10_3390_cancers12113316 crossref_primary_10_1007_s11739_021_02784_y crossref_primary_10_1055_s_0040_1716813 crossref_primary_10_3390_jcm11102803 crossref_primary_10_3389_fimmu_2022_919762 crossref_primary_10_3390_v15030756 crossref_primary_10_1016_j_idcr_2022_e01528 crossref_primary_10_1016_j_htct_2021_01_006 crossref_primary_10_1080_10428194_2021_1966782 crossref_primary_10_7759_cureus_12064 crossref_primary_10_1111_bjh_17850 crossref_primary_10_3389_fimmu_2020_609198 crossref_primary_10_1186_s12879_021_06472_2 crossref_primary_10_1007_s11912_023_01419_z crossref_primary_10_3390_biomedicines10123069 crossref_primary_10_1186_s12879_022_07347_w |
| Cites_doi | 10.1056/NEJMoa2001017 10.1016/S2213-2600(20)30071-0 10.1016/S0140-6736(20)30185-9 10.1016/S0140-6736(20)30251-8 10.1038/s41564-020-0695-z 10.1016/S1470-2045(20)30175-3 10.1016/S1470-2045(20)30150-9 10.1200/JCO.18.00374 10.1056/NEJMp2003762 10.1016/S0140-6736(20)30183-5 10.1080/22221751.2020.1719902 10.1016/S1470-2045(20)30096-6 10.1038/s41375-018-0040-1 10.1038/s41375-019-0388-x 10.1001/jama.2020.1585 10.1016/S0140-6736(20)30211-7 10.1056/NEJMoa2002032 10.1001/jamaoncol.2020.0980 10.1016/S1473-3099(20)30086-4 10.7326/m20-1133 10.1001/jama.2020.2648 10.1016/S2213-2600(20)30079-5 |
| ContentType | Journal Article |
| Copyright | The Author(s), under exclusive licence to Springer Nature Limited 2020 COPYRIGHT 2020 Nature Publishing Group The Author(s), under exclusive licence to Springer Nature Limited 2020. |
| Copyright_xml | – notice: The Author(s), under exclusive licence to Springer Nature Limited 2020 – notice: COPYRIGHT 2020 Nature Publishing Group – notice: The Author(s), under exclusive licence to Springer Nature Limited 2020. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QL 7RV 7T5 7T7 7TM 7TO 7U9 7X7 7XB 88E 8AO 8C1 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI C1K CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. KB0 LK8 M0S M1P M7N M7P NAPCQ P64 PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.1038/s41375-020-0836-7 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Nursing & Allied Health Database Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts Virology and AIDS Abstracts ProQuest Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Public Health Database Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Journals Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Database ProQuest Central ProQuest Natural Science Collection (Hollins) Environmental Sciences and Pollution Management ProQuest One ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Nursing & Allied Health Database (Alumni Edition) Biological Sciences Health & Medical Collection (Alumni) Medical Database Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Nursing & Allied Health Premium Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student Oncogenes and Growth Factors Abstracts ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection ProQuest Central China Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection Industrial and Applied Microbiology Abstracts (Microbiology A) ProQuest Central (New) ProQuest Medical Library (Alumni) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts Nursing & Allied Health Premium ProQuest Health & Medical Complete ProQuest One Academic UKI Edition ProQuest Nursing & Allied Health Source (Alumni) Engineering Research Database ProQuest One Academic ProQuest One Academic (New) Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Pharma Collection ProQuest Central ProQuest Health & Medical Research Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Public Health ProQuest Nursing & Allied Health Source ProQuest SciTech Collection ProQuest Medical Library Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE ProQuest Central Student MEDLINE - Academic ProQuest Central Student |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: http://www.proquest.com/pqcentral?accountid=15518 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Public Health |
| EISSN | 1476-5551 |
| EndPage | 1645 |
| ExternalDocumentID | PMC7180672 A625609952 32332856 10_1038_s41375_020_0836_7 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | China United Kingdom |
| GeographicLocations_xml | – name: China – name: United Kingdom |
| GrantInformation_xml | – fundername: Fundamental Research Funds for the Central Universities; 2020kfyXGYJ086 – fundername: National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme – fundername: National Natural Science Foundation of China (National Science Foundation of China) grantid: 81974009; 81974221 funderid: https://doi.org/10.13039/501100001809 – fundername: National Natural Science Foundation of China (National Science Foundation of China) grantid: 81974221 – fundername: National Natural Science Foundation of China (National Science Foundation of China) grantid: 81974009 – fundername: ; – fundername: ; grantid: 81974009; 81974221 |
| GroupedDBID | --- -Q- .55 .XZ 0R~ 29L 2WC 36B 39C 3V. 4.4 406 53G 5GY 5RE 70F 7RV 7X7 88E 8AO 8C1 8FI 8FJ 8R4 8R5 AACDK AANZL AAQQT AASDW AASML AATNV AAWTL AAYZH AAZLF ABAKF ABAWZ ABDBF ABJNI ABLJU ABOCM ABUWG ABZZP ACAOD ACGFO ACGFS ACKTT ACMJI ACPRK ACRQY ACUHS ACZOJ ADBBV ADHDB AEFQL AEJRE AEMSY AENEX AEVLU AEXYK AFBBN AFFNX AFKRA AFRAH AFSHS AGAYW AGHAI AGQEE AHMBA AHSBF AIGIU AILAN AJRNO ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS AMYLF ASPBG AVWKF AXYYD AZFZN B0M BAWUL BBNVY BENPR BHPHI BKEYQ BKKNO BPHCQ BVXVI CAG CCPQU COF CS3 DIK DNIVK DPUIP DU5 E3Z EAD EAP EBC EBD EBLON EBS EBX EE. EIOEI EJD EMB EMK EMOBN EPL ESX EX3 F5P FDQFY FEDTE FERAY FIGPU FIZPM FSGXE FYUFA HCIFZ HMCUK HVGLF HZ~ IAO IH2 IHR IHW INH INR ITC IWAJR JSO JZLTJ KQ8 LGEZI LOTEE M1P M7P N9A NADUK NAO NAPCQ NQJWS NXXTH O9- OK1 OVD P2P P6G PQQKQ PROAC PSQYO Q2X RNS RNT RNTTT ROL SNX SNYQT SOHCF SOJ SRMVM SV3 SWTZT TAOOD TBHMF TDRGL TEORI TR2 TSG TUS UDS UKHRP WOW X7M Y6R ZGI ZXP ~8M AAYXX ABBRH ABDBE ABFSG ABRTQ ACSTC AEZWR AFDZB AFHIU AHWEU AIXLP ATHPR AYFIA CITATION PUEGO CGR CUY CVF ECM EIF NPM ACMFV PHGZM PHGZT AEIIB PMFND 7QL 7T5 7T7 7TM 7TO 7U9 7XB 8FD 8FE 8FH 8FK AZQEC C1K DWQXO FR3 GNUQQ H94 K9. LK8 M7N P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS 7X8 5PM |
| ID | FETCH-LOGICAL-c596t-655e89ae4503169c74855d66f7b28639f31a4cc3d60710203043cc7912f53a7e3 |
| IEDL.DBID | 7X7 |
| ISSN | 0887-6924 1476-5551 |
| IngestDate | Tue Sep 30 15:31:23 EDT 2025 Thu Sep 04 18:50:07 EDT 2025 Fri Jul 25 08:55:53 EDT 2025 Sat Aug 23 12:43:00 EDT 2025 Tue Jun 17 21:01:26 EDT 2025 Tue Jun 10 20:49:48 EDT 2025 Thu May 22 21:06:10 EDT 2025 Wed Feb 19 02:30:00 EST 2025 Wed Oct 01 01:52:30 EDT 2025 Thu Apr 24 23:11:30 EDT 2025 Fri Feb 21 02:38:41 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| License | This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c596t-655e89ae4503169c74855d66f7b28639f31a4cc3d60710203043cc7912f53a7e3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| ORCID | 0000-0001-7884-0745 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC7180672 |
| PMID | 32332856 |
| PQID | 2408812782 |
| PQPubID | 30521 |
| PageCount | 9 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_7180672 proquest_miscellaneous_2394879767 proquest_journals_2474982161 proquest_journals_2408812782 gale_infotracmisc_A625609952 gale_infotracacademiconefile_A625609952 gale_healthsolutions_A625609952 pubmed_primary_32332856 crossref_citationtrail_10_1038_s41375_020_0836_7 crossref_primary_10_1038_s41375_020_0836_7 springer_journals_10_1038_s41375_020_0836_7 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-06-01 |
| PublicationDateYYYYMMDD | 2020-06-01 |
| PublicationDate_xml | – month: 06 year: 2020 text: 2020-06-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | London |
| PublicationPlace_xml | – name: London – name: England |
| PublicationTitle | Leukemia |
| PublicationTitleAbbrev | Leukemia |
| PublicationTitleAlternate | Leukemia |
| PublicationYear | 2020 |
| Publisher | Nature Publishing Group UK Nature Publishing Group |
| Publisher_xml | – name: Nature Publishing Group UK – name: Nature Publishing Group |
| References | Lu, Zhao, Li, Niu, Yang, Wu (CR2) 2020; 395 Liang, Guan, Chen, Wang, Li, Xu (CR14) 2020; 21 CR4 Wang, Horby, Hayden, Gao (CR7) 2020; 395 CR5 Huang, Wang, Li, Ren, Zhao, Hu (CR6) 2020; 395 Taplitz, Kennedy, Bow, Crews, Gleason, Hawley (CR21) 2018; 36 Chen, Zhou, Dong, Qu, Gong, Han (CR10) 2020; 395 CR16 CR15 (CR17) 2020; 21 Zhang, Zhou, Yang, Peng, Wang, Chen (CR24) 2020; 8 CR13 CR12 CR23 CR22 Xia, Jin, Zhao, Li, Shen (CR18) 2020; 21 Chan, Kok, Zhu, Chu, To, Yuan (CR1) 2020; 9 Wang, Hu, Hu, Zhu, Liu, Zhang (CR9) 2020; 323 Gorbalenya, Baker, Baric, de Groot, Drosten, Gulyaeva (CR3) 2020; 5 Maschmeyer, De Greef, Mellinghoff, Nosari, Thiebaut-Bertrand, Bergeron (CR20) 2019; 33 Gates (CR8) 2020; 382 Zhu, Zhang, Wang, Li, Yang, Song (CR11) 2020; 382 Ludwig, Delforge, Facon, Einsele, Gay, Moreau (CR19) 2018; 32 N Zhu (836_CR11) 2020; 382 AE Gorbalenya (836_CR3) 2020; 5 The Lancet O. (836_CR17) 2020; 21 W Liang (836_CR14) 2020; 21 RA Taplitz (836_CR21) 2018; 36 H Ludwig (836_CR19) 2018; 32 836_CR16 836_CR4 836_CR15 836_CR13 836_CR5 836_CR12 836_CR23 836_CR22 N Chen (836_CR10) 2020; 395 G Maschmeyer (836_CR20) 2019; 33 R Lu (836_CR2) 2020; 395 D Wang (836_CR9) 2020; 323 C Wang (836_CR7) 2020; 395 JF-W Chan (836_CR1) 2020; 9 C Huang (836_CR6) 2020; 395 Y Xia (836_CR18) 2020; 21 B Gates (836_CR8) 2020; 382 J Zhang (836_CR24) 2020; 8 32528043 - Leukemia. 2020 Aug;34(8):2265-2270 32457356 - Leukemia. 2020 Jul;34(7):1957-1960 32641731 - Leukemia. 2020 Sep;34(9):2536-2538 32801310 - Leukemia. 2020 Oct;34(10):2809-2812 32475990 - Leukemia. 2020 Jul;34(7):1961-1963 |
| References_xml | – ident: CR22 – volume: 382 start-page: 727 year: 2020 end-page: 33 ident: CR11 article-title: A novel coronavirus from patients with pneumonia in China, 2019 publication-title: N Engl J Med doi: 10.1056/NEJMoa2001017 – volume: 8 start-page: e11 year: 2020 end-page: 2 ident: CR24 article-title: Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics publication-title: Lancet Resp Med doi: 10.1016/S2213-2600(20)30071-0 – volume: 395 start-page: 470 year: 2020 end-page: 3 ident: CR7 article-title: A novel coronavirus outbreak of global health concern publication-title: Lancet doi: 10.1016/S0140-6736(20)30185-9 – ident: CR4 – ident: CR15 – ident: CR16 – ident: CR12 – volume: 395 start-page: 565 year: 2020 end-page: 74 ident: CR2 article-title: Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding publication-title: Lancet doi: 10.1016/S0140-6736(20)30251-8 – volume: 5 start-page: 536 year: 2020 end-page: 44 ident: CR3 article-title: The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2 publication-title: Nat Microbiol doi: 10.1038/s41564-020-0695-z – ident: CR13 – volume: 21 start-page: 467 year: 2020 ident: CR17 article-title: COVID-19: global consequences for oncology publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30175-3 – volume: 21 start-page: e180 year: 2020 ident: CR18 article-title: Risk of COVID-19 for patients with cancer publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30150-9 – volume: 36 start-page: 3043 year: 2018 end-page: 54 ident: CR21 article-title: Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update publication-title: J Clin Oncol doi: 10.1200/JCO.18.00374 – volume: 382 start-page: 692 year: 2020 end-page: 4 ident: CR8 article-title: Responding to Covid-19—a once-in-a-century pandemic? publication-title: N Engl J Med doi: 10.1056/NEJMp2003762 – volume: 395 start-page: 497 year: 2020 end-page: 506 ident: CR6 article-title: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China publication-title: Lancet doi: 10.1016/S0140-6736(20)30183-5 – ident: CR5 – volume: 9 start-page: 221 year: 2020 end-page: 36 ident: CR1 article-title: Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan publication-title: Emerg Microbes Infect doi: 10.1080/22221751.2020.1719902 – volume: 21 start-page: 335 year: 2020 end-page: 7 ident: CR14 article-title: Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30096-6 – volume: 32 start-page: 1542 year: 2018 end-page: 60 ident: CR19 article-title: Prevention and management of adverse events of novel agents in multiple myeloma: a consensus of the European Myeloma Network publication-title: Leukemia doi: 10.1038/s41375-018-0040-1 – volume: 33 start-page: 844 year: 2019 end-page: 62 ident: CR20 article-title: Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. A position paper by the European Conference on Infections in Leukemia (ECIL) publication-title: Leukemia doi: 10.1038/s41375-019-0388-x – volume: 323 start-page: 1061 year: 2020 end-page: 9 ident: CR9 article-title: Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China publication-title: JAMA doi: 10.1001/jama.2020.1585 – ident: CR23 – volume: 395 start-page: 507 year: 2020 end-page: 13 ident: CR10 article-title: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study publication-title: Lancet doi: 10.1016/S0140-6736(20)30211-7 – ident: 836_CR23 – ident: 836_CR22 – ident: 836_CR5 doi: 10.1056/NEJMoa2002032 – volume: 395 start-page: 507 year: 2020 ident: 836_CR10 publication-title: Lancet doi: 10.1016/S0140-6736(20)30211-7 – volume: 21 start-page: 467 year: 2020 ident: 836_CR17 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30175-3 – ident: 836_CR15 doi: 10.1001/jamaoncol.2020.0980 – volume: 323 start-page: 1061 year: 2020 ident: 836_CR9 publication-title: JAMA doi: 10.1001/jama.2020.1585 – volume: 32 start-page: 1542 year: 2018 ident: 836_CR19 publication-title: Leukemia doi: 10.1038/s41375-018-0040-1 – ident: 836_CR12 doi: 10.1016/S1473-3099(20)30086-4 – volume: 9 start-page: 221 year: 2020 ident: 836_CR1 publication-title: Emerg Microbes Infect doi: 10.1080/22221751.2020.1719902 – volume: 382 start-page: 692 year: 2020 ident: 836_CR8 publication-title: N Engl J Med doi: 10.1056/NEJMp2003762 – volume: 21 start-page: e180 year: 2020 ident: 836_CR18 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30150-9 – volume: 21 start-page: 335 year: 2020 ident: 836_CR14 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(20)30096-6 – volume: 8 start-page: e11 year: 2020 ident: 836_CR24 publication-title: Lancet Resp Med doi: 10.1016/S2213-2600(20)30071-0 – volume: 382 start-page: 727 year: 2020 ident: 836_CR11 publication-title: N Engl J Med doi: 10.1056/NEJMoa2001017 – volume: 5 start-page: 536 year: 2020 ident: 836_CR3 publication-title: Nat Microbiol doi: 10.1038/s41564-020-0695-z – volume: 395 start-page: 497 year: 2020 ident: 836_CR6 publication-title: Lancet doi: 10.1016/S0140-6736(20)30183-5 – ident: 836_CR16 doi: 10.7326/m20-1133 – volume: 395 start-page: 470 year: 2020 ident: 836_CR7 publication-title: Lancet doi: 10.1016/S0140-6736(20)30185-9 – ident: 836_CR4 doi: 10.1001/jama.2020.2648 – volume: 395 start-page: 565 year: 2020 ident: 836_CR2 publication-title: Lancet doi: 10.1016/S0140-6736(20)30251-8 – ident: 836_CR13 doi: 10.1016/S2213-2600(20)30079-5 – volume: 33 start-page: 844 year: 2019 ident: 836_CR20 publication-title: Leukemia doi: 10.1038/s41375-019-0388-x – volume: 36 start-page: 3043 year: 2018 ident: 836_CR21 publication-title: J Clin Oncol doi: 10.1200/JCO.18.00374 – reference: 32641731 - Leukemia. 2020 Sep;34(9):2536-2538 – reference: 32475990 - Leukemia. 2020 Jul;34(7):1961-1963 – reference: 32528043 - Leukemia. 2020 Aug;34(8):2265-2270 – reference: 32457356 - Leukemia. 2020 Jul;34(7):1957-1960 – reference: 32801310 - Leukemia. 2020 Oct;34(10):2809-2812 |
| SSID | ssj0014766 |
| Score | 2.6975884 |
| Snippet | Infection with SARS-CoV-2, the cause of coronavirus infectious disease–19 (COVID-19), has caused a pandemic with >850,000 cases worldwide and increasing.... Infection with SARS-CoV-2, the cause of coronavirus infectious disease-19 (COVID-19), has caused a pandemic with >850,000 cases worldwide and increasing.... |
| SourceID | pubmedcentral proquest gale pubmed crossref springer |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1637 |
| SubjectTerms | 692/699/1541/1990 692/699/255 Adult Betacoronavirus Blood cancer Cancer Cancer Research China - epidemiology Cohort Studies Comparative analysis Confidence intervals Coronavirus Infections - complications Coronavirus Infections - transmission Coronavirus Infections - virology Coronaviruses COVID-19 Critical Care Medicine Development and progression Fatalities Female Health aspects Health care Health care industry Hematologic Neoplasms - complications Hematologic Neoplasms - epidemiology Hematology Humans Incidence Infectious Disease Transmission, Patient-to-Professional - statistics & numerical data Infectious diseases Intensive Internal Medicine Male Medicine Medicine & Public Health Middle Aged Oncology Oncology, Experimental Pandemics Pneumonia, Viral - complications Pneumonia, Viral - transmission Pneumonia, Viral - virology Public health Risk analysis Risk factors SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Viral diseases Young Adult |
| Title | COVID-19 in persons with haematological cancers |
| URI | https://link.springer.com/article/10.1038/s41375-020-0836-7 https://www.ncbi.nlm.nih.gov/pubmed/32332856 https://www.proquest.com/docview/2408812782 https://www.proquest.com/docview/2474982161 https://www.proquest.com/docview/2394879767 https://pubmed.ncbi.nlm.nih.gov/PMC7180672 |
| Volume | 34 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAFT databaseName: Open Access Digital Library customDbUrl: eissn: 1476-5551 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0014766 issn: 0887-6924 databaseCode: KQ8 dateStart: 19970101 isFulltext: true titleUrlDefault: http://grweb.coalliance.org/oadl/oadl.html providerName: Colorado Alliance of Research Libraries – providerCode: PRVLSH databaseName: SpringerLink Journals customDbUrl: mediaType: online eissn: 1476-5551 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0014766 issn: 0887-6924 databaseCode: AFBBN dateStart: 19970101 isFulltext: true providerName: Library Specific Holdings – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1476-5551 dateEnd: 20241001 omitProxy: true ssIdentifier: ssj0014766 issn: 0887-6924 databaseCode: BENPR dateStart: 19970201 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Health & Medical Collection customDbUrl: eissn: 1476-5551 dateEnd: 20241001 omitProxy: true ssIdentifier: ssj0014766 issn: 0887-6924 databaseCode: 7X7 dateStart: 19970201 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3ra9RAEF-0BRFEtL5Sa40gCMpyl33vJ7k7e1Shp4iV-7Ykmz1akNy1uf7_zmwemoP2S-7DziXZyTx-O7MzS8h7ZcvAWKmpHJeGCuk5NbLIKPhuY71W4NSxUPhsoU7PxbelXLYBt7rdVtnZxGioy7XHGPmICS2sYQBQPm-uKJ4ahdnV9giN-2Q_A6iCUq2X_YIrE7rJVaIiKVhodFlNbkY1GG-Ntcnj2J-Z6oFf2rXO_7mn3a2TO_nT6JbmT8jjFk-mk0YAnpJ7oTogD87ajPkBedTE5dKm3OgZGc2-__76hWY2vazSTYTbdYrB2PQix_atnS1MPYrDdf2cnM9Pfs1OaXtoAvXSqi1VUgZj8yAkqKsCdmP3l1KplS6YATiy4lkuvOeliuACM6Pce20ztpI814G_IHvVugqvSGrDSthCBuGZFQC7Cu15ga3GhZaFNzYh445lzrcdxfFgiz8uZra5cQ2XHTzGIZedTsjH_i-bpp3GXcRv8Tu4piK0V0U3UYjTrJUsIR8iBSojPNnnbU0BvD-2tRpQHg0oQYn8cLj71q5V4tph9zfAP4ChbhnuJDIh7_phvDHuW6vC-gZouIUVIUA-mMzLRnL6eXPGOTNSJUQPZKonwM7fw5Hq8iJ2AAdAgSn0hHzqpO_fa93KzsO7J_GaPGRRHTDCdET2ttc34Q0Arm1xHLUKrmaWHZP9yXw6XcDv9GTx4-dfr8kj1w |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3da9RAEB9qBRVEtH40Wm0ERVDCXfYz-yBSWsud7dWXVu5tm2z2aKHkzuaK-E_5NzqTL81B-9bX7CTZj5md3-7s_BbgnTK5ZyzXkRzmSSSk41EiszhC350YpxU6dUoUnhyp0Yn4NpXTNfjT5sLQscp2Tqwm6nzuaI98wIQWJmEIUL4sfkZ0axRFV9srNGq1OPC_f-GSrfw83sPxfc_Y_tfj3VHU3CoQOWnUMlJS-sSkXkjUZ4X1IXqUXKmZzliC_nrG41Q4x3NVeV8KHXLntInZTPJUe47fvQN3BT4nrn497RZ4sdB1bJQMV-HCpo2i8mRQorPQlAs9rPigI93zg6ve4D93uHpUcyVeW7nB_cfwqMGv4U6tcE9gzRcbcG_SROg34GG9DxjW6U1PYbD7_cd4L4pNeF6EiwrelyFt_oZnKdHFtnNv6Ej9LstncHIr3fkc1ot54TchNH4mTCa9cMwIhHmZdjwjanOhZeYSE8Cw7TLrGgZzukjjwlaRdJ7Yupct_sZSL1sdwMfulUVN33GT8DaNg60zUDvTtzuKcKExkgXwoZIg48c_u7TJYcD6E41WT3KrJ4lG6_rF7VjbZtIoLbHNId5CzHZNcWsBAbztiunDdE6u8PMrlOEGV6AIMbExL2rN6drNGecskSoA3dOpToCYxvslxflZxTiOAIZC9gF8arXvX7Wu7c6XNzdiG-6PjieH9nB8dPAKHrDKNGh3awvWl5dX_jWCvWX2prKwEE5v26T_All5WhY |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3da9RAEB9qhSKIaP2KVhtBEZRwl_3MPoiUnkfP2uqDlXtbk82GFiR3NlfEf82_zpl8aQ7atz7vZLM7O1-7s_NbgJfK5J6xXEdynCeRkI5HicziCH13YpxW6NSpUPjoWB2ciI9zOd-AP10tDF2r7GxibajzhaMz8hETWpiEYYAyKtprEV8m0_fLnxG9IEWZ1u45jUZEDv3vX7h9q97NJrjWrxibfvi6fxC1LwxEThq1ipSUPjGpFxJlW-HYCColV6rQGUvQdxc8ToVzPFe1J6Y0IndOm5gVkqfac-z3BtzUXHC6Tqbn_WYvFrrJk5ISK9zkdBlVnowqdBya6qLHNTZ0pAc-cd0z_Oca169truVua5c4vQt32lg23GuE7x5s-HIbto7abP023G7OBMOm1Ok-jPY_f5tNotiEZ2W4rEP9KqSD4PA0JejYzg6HjkTxvHoAJ9fCzoewWS5K_xhC4wthMumFY0ZgyJdpxzOCORdaZi4xAYw7llnXopnToxo_bJ1V54ltuGzxN5a4bHUAb_pPlg2Ux1XEu7QOtqlG7c2A3VMUIxojWQCvawoyBPhnl7b1DDh-gtQaUO4MKFGB3bC5W2vbGpDKEvIcxl4Yv13S3GlDAC_6ZuqY7syVfnGBNNzgbhTDTZzMo0Zy-nlzxjlLpApAD2SqJyDU8WFLeXZao49jMEPp-wDedtL3b1iXsvPJ1ZPYhS1UZvtpdnz4FG6xWjPooGsHNlfnF_4Zxn2r7HmtYCF8v26N_gsy3V5R |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=COVID-19+in+persons+with+haematological+cancers&rft.jtitle=Leukemia&rft.au=He%2C+Wenjuan&rft.au=Chen%2C+Lei&rft.au=Chen%2C+Li&rft.au=Yuan%2C+Guolin&rft.date=2020-06-01&rft.pub=Nature+Publishing+Group+UK&rft.issn=0887-6924&rft.eissn=1476-5551&rft.volume=34&rft.issue=6&rft.spage=1637&rft.epage=1645&rft_id=info:doi/10.1038%2Fs41375-020-0836-7&rft.externalDocID=10_1038_s41375_020_0836_7 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0887-6924&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0887-6924&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0887-6924&client=summon |